University of Iowa (UI) Pharmaceuticals, the largest and most experienced university-affiliated FDA-registered pharmaceutical manufacturing facility in the United States, celebrates a new achievement this month. MimiVax, Inc. and UI Pharmaceuticals are proud to announce the successful clinical manufacture of SurVaxM, a novel immunotherapeutic vaccine targeting Glioblastoma, at UI Pharmaceutical's recently qualified $26M sterile manufacturing facility. This collaboration combines MimiVax's innovative research with UIP's expertise in formulation development and sterile production, accelerating the path to potentially transformative therapies for patients.
Tuesday, January 14, 2025